Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932451 · ClinicalTrials.gov registry record · Phase 2
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,069
- Enrollment target
NCT00932451 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 1,069 participants.
The verdict
NCT00932451, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,069 participants
- Enrollment target
Study Summary
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
Interventions
- DRUG PF-02341066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,069 participants |
| Start Date | 2010-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932451
The ClinicalTrials.gov registry entry for NCT00932451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,069 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-02341066 is the first listed.
NCT00932451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932451 about?
NCT00932451 is a clinical study titled "An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene". This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081...
What is the current status of trial NCT00932451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,069 participants. The study started on 2010-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00932451?
The interventions under investigation include: PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00932451?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.